Cabozantinib: a new first-line option for papillary renal cell carcinoma?
Mené sur 152 patients atteints d'un carcinome papillaire à cellules rénales de stade avancé, cet essai de phase II compare l'efficacité, du point de vue de la survie sans progression, et la toxicité du sunitinib, du cabozantinib, du crizotinib et du savolitinib
Papillary renal cell carcinoma (PRCC) is the most frequent subtype of non-clear-cellrenal cell carcinoma (RCC); however, it remains a rare and heterogeneous malignancy. PRCC is divided into type1 and type 2, on the basis of different histological, molecular, and prognostic features. Alterations in the MET pathway are frequent in PRCC, mostly observed in type 1 tumours(80%), but have also been described in up to half of type 2 tumours.
The Lancet , commentaire, 2020